#1 Clinical Trials Search in Europe

(2R)-N-[3-(5-Fluoro-2-{[2-Fluoro-3-(Methylsulfonyl)Phenyl]Amino}-4-Pyrimidinyl)-1H-Indol-7-Yl]-3-Methoxy-2-(4-Methyl-1-Piperazinyl)Propanamide-1-Hydroxy-2-Naphthoic Acid

This article discusses recent clinical trials investigating the use of AZD4604, a novel drug developed by AstraZeneca, for the treatment of moderate to severe asthma. AZD4604 is being studied as a potential new therapy for patients whose asthma is not well-controlled with current treatments. The trials aim to evaluate the safety and effectiveness of AZD4604 in improving lung function, reducing inflammation, and controlling asthma symptoms in adult patients.

Table of Contents

What is AZD4604?

AZD4604 is a new medication being developed to treat moderate to severe asthma in adults[1]. It’s also known by its chemical name, which is quite long: (2R)-N-[3-(5-FLUORO-2-{[2-FLUORO-3-(METHYLSULFONYL)PHENYL]AMINO}-4-PYRIMIDINYL)-1H-INDOL-7-YL]-3-METHOXY-2-(4-METHYL-1-PIPERAZINYL)PROPANAMIDE-1-HYDROXY-2-NAPHTHOIC ACID[2]. Another name for it is AZD4604 xinafoate[2]. This medication comes in the form of an inhalation powder, which means you breathe it in through your mouth to get it into your lungs[1][2].

How Does AZD4604 Work?

AZD4604 is a type of medication known as a small molecule[1]. While the exact mechanism isn’t fully explained in the available information, it’s being studied for its effects on airway inflammation, which is a key problem in asthma[2]. The medication appears to work by affecting certain genes and proteins in the airways, potentially helping to reduce inflammation and improve breathing[2].

Who Might Benefit from AZD4604?

AZD4604 is being developed for adults with moderate to severe asthma who are not well-controlled on their current medications[1]. Specifically, it’s aimed at people who are already taking:

  • Medium to high doses of inhaled corticosteroids (ICS)
  • Long-acting beta-agonists (LABA)
If you’re still having asthma symptoms or attacks despite using these medications, you might be the type of patient that AZD4604 is designed to help[1].

Current Research on AZD4604

AZD4604 is currently being studied in clinical trials. These are research studies that help determine if a new medication is safe and effective. Two main studies are happening right now:

  1. A 12-week study looking at how well AZD4604 works compared to a placebo (a treatment with no active ingredient) in improving lung function and reducing asthma symptoms[1].
  2. A 4-week study examining how AZD4604 affects inflammation in the airways and certain biological markers related to asthma[2].
These studies are considered Phase 2 trials, which means the medication is still in a relatively early stage of testing in humans[1][2].

Potential Benefits of AZD4604

Based on the ongoing research, AZD4604 may potentially offer several benefits for people with moderate to severe asthma:

  • Improved lung function, measured by a test called FEV1 (forced expiratory volume in 1 second)[1]
  • Reduced inflammation in the airways[2]
  • Better control of asthma symptoms[1]
  • Fewer asthma attacks or exacerbations[1]
  • Improved quality of life for people with asthma[1]
However, it’s important to note that these potential benefits are still being studied and haven’t been proven yet[1][2].

Safety Considerations

As with any new medication, safety is a crucial consideration. The clinical trials for AZD4604 are carefully designed to monitor for any side effects or safety concerns[1][2]. Some key points about safety:

  • People with certain health conditions or a history of specific illnesses may not be able to participate in the trials[1][2].
  • The studies exclude people who smoke or have a significant history of smoking[1][2].
  • Participants are closely monitored throughout the studies for any adverse effects[1][2].
It’s important to remember that AZD4604 is still an experimental medication. More research is needed to fully understand its safety profile and potential long-term effects[1][2].

Conclusion

AZD4604 represents a potential new treatment option for adults with moderate to severe asthma who are not well-controlled on current therapies. While the research is still ongoing, this medication could offer hope for better asthma management in the future. As always, if you have questions about your asthma treatment or are interested in clinical trials, it’s best to discuss these with your healthcare provider.

Aspect Details
Drug Name AZD4604
Manufacturer AstraZeneca AB
Administration Inhalation powder
Target Population Adults with moderate to severe asthma uncontrolled on medium-high dose ICS-LABA
Primary Objectives Evaluate clinical efficacy, effect on airway inflammation, and gene expression in airway cells
Secondary Objectives Assess effects on lung function, asthma symptoms, quality of life, and cellular pathology in airways
Key Measurements FEV1, FeNO, ACQ-6 scores, STAT phosphorylation, gene expression in bronchial brushings
Study Design Randomized, double-blind, placebo-controlled trials
Treatment Duration 4-12 weeks, depending on the specific trial

FAQ

  • What is AZD4604? AZD4604 is a new drug being developed by AstraZeneca for the treatment of moderate to severe asthma. It is an inhalation powder that contains a chemical compound designed to target specific pathways involved in airway inflammation and asthma symptoms.
  • Who is eligible to participate in these clinical trials? The trials are primarily focused on adult patients (18 years and older) with moderate to severe asthma that is not well-controlled on current treatments, such as medium to high-dose inhaled corticosteroids and long-acting beta-agonists. Specific eligibility criteria may vary between trials.
  • What are the main goals of these clinical trials? The main goals are to evaluate the effectiveness and safety of AZD4604 in improving lung function, reducing airway inflammation, and controlling asthma symptoms. The trials also aim to understand how the drug works in the body and its effects on various biomarkers related to asthma.
  • How is AZD4604 administered? AZD4604 is administered as an inhalation powder. Patients in the trials typically inhale the medication twice daily using a special inhaler device.
  • What are some of the key measurements being taken in these trials? Key measurements include changes in lung function (such as FEV1), levels of exhaled nitric oxide (FeNO) which indicates airway inflammation, asthma symptom scores, and quality of life assessments. Some trials also involve more detailed analyses of airway cells and gene expression through procedures like bronchoscopy.

Ongoing Clinical Trials on (2R)-N-[3-(5-Fluoro-2-{[2-Fluoro-3-(Methylsulfonyl)Phenyl]Amino}-4-Pyrimidinyl)-1H-Indol-7-Yl]-3-Methoxy-2-(4-Methyl-1-Piperazinyl)Propanamide-1-Hydroxy-2-Naphthoic Acid

  • Study on the Effects of AZD4604 on Airway Inflammation in Adults with Asthma

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany Spain

  • Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Denmark France Germany The Netherlands Spain +1

Glossary

  • FEV1: Forced Expiratory Volume in 1 second. This is a measure of how much air a person can exhale in one second, which is used to assess lung function and the severity of airflow obstruction.
  • FeNO: Fractional exhaled Nitric Oxide. This is a test that measures the level of nitric oxide in a person's breath, which can indicate the amount of inflammation in the airways.
  • ICS-LABA: Inhaled Corticosteroid-Long-Acting Beta-Agonist. This is a combination therapy commonly used in asthma treatment, where the corticosteroid reduces inflammation and the beta-agonist helps to open up the airways.
  • ACQ-6: Asthma Control Questionnaire-6. This is a standardized questionnaire used to assess how well a patient's asthma symptoms are controlled.
  • Bronchoscopy: A medical procedure that allows doctors to look inside the airways of the lungs using a thin, flexible tube called a bronchoscope. In these trials, it's used to collect samples from the airways.
  • STAT phosphorylation: A cellular process involved in transmitting signals within cells. In the context of these trials, it's being studied to understand how AZD4604 affects certain inflammatory pathways in asthma.
  • Biomarker: A measurable indicator of a biological state or condition. In asthma research, biomarkers can help track disease activity or response to treatment.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs. Some patients in these trials may receive a placebo instead of AZD4604 to compare outcomes.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-azd4604-for-adults-with-moderate-to-severe-asthma-uncontrolled-on-medium-high-dose-ics-laba/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-azd4604-on-airway-inflammation-in-adults-with-asthma/